We are well into the second half of 2017. As yet another month comes to an end, let’s take a look back at some of the FDA approval announcements that hit the headlines in July.

Endari, approved on July 7, 2017 for patients with sickle cell disease, marks the first approval for this rare blood disorder in nearly 20 years. Endari is manufactured by privately-held Emmaus Medical Inc.

ALSO READ: Where The Paypal Mafia Ended Up

Health care giant Johnson & Johnson subsidiary Janssen Biotech Inc.’s Tremfya was approved for the treatment of adult patients with moderate-to-severe plaque psoriasis on July 13, 2017. This drug becomes the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a key role in plaque psoriasis.

On July 17, 2017, the FDA approved Puma Biotechnology Inc.’s (PBYI) Nerlynx, the first extended adjuvant therapy for early-stage, HER2-postive breast cancer.

Another new drug that was given thumbs up by the FDA is Gilead Sciences Inc.’s (GILD) Vosevi for hepatitis C, approved on July 18, 2017. Vosevi is the first treatment approved for patients who have been previously treated with the direct-acting antiviral drug Sofosbuvir or other drugs for HCV that inhibit a protein called NS5A.

Now, let’s take a look at the biotech stocks awaiting word from the FDA in August.Aspect Imaging Ltd’s Embrace Neonatal MRI System received FDA clearance on July 20, 2017, becoming the first neonatal magnetic resonance imaging device to get a regulatory green light.

Practice trading these Biotech Stocks on WSS now!

Gilead Sciences Inc.’s (GILD)

Johnson & Johnson (JNJ)


First Seen on RTTNews

Important Reminder!

The Motley Fool Stock Advisor ranks as our #1 Best Investment Newsletter for the third year in a row.

Their stock recommendations continue to beat all of the other newsletters and they maintain a very high accuracy of their picks. Their 24 stock picks from 2018 have outperformed the market by an average of 44% as of July 7, 2019. Read that again. I didn’t say their stock picks are up an average of 44%, I said they have BEAT THE MARKET by 44%.

No other newsletter comes close to that. You may have seen the Motley Fool’ advertisements that their picks are up 367% compared to the market’s 80%. Is The Motley Fool’s Stock Advisor really as good as they claim?

Our results, at least since January 2016, suggest YES. You can now get their latest stock picks for ONLY $19/month or $99/year. But this is a special limited time offer. It expires tonight at midnight.

Get the Motley Fool's Latest picks

P.s. this offer is still backed by their 30-day guarantee